Min Zhong
Executive Director, Medicinal Chemistry @Assembly Biosciences, Inc.
Signup · Get unlimited contacts
WORK HISTORY
Executive Director, Medicinal Chemistry @Assembly Biosciences, Inc.
EDUCATION
Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
PhD, Organic Chemistry
SKILLS
ABOUT MIN ZHONG
Collaborative, organized, and goal-oriented project/team/functional leader Creative medicinal chemist with strong data analysis and problem-solving capability Extensive working experience as a solid contributor in fast-paced small biotech/pharmaceutical companies, including virtual companies Rich small molecule drug discovery experience across multiple therapeutic areas, including infectious disease, immunology, oncology, cardiovascular diseases, CNS, and metabolic diseases Expertise in medicinal chemistry (fragment/structure/property-based design, hit-to-lead, lead optimization, and selection of development candidate) and process chemistry (route scouting) with in-depth knowledge on biology, DMPK, and pre-clinical evaluations of drug development candidates Proven track record of success in project/team management by leading teams that achieved milestones of internal projects and/or collaboration projects with large pharmaceutical companies (e.g, Merck, Biogen, and Sanofi) and delivered multiple clinical candidates Experience in recruiting, mentoring, and developing medicinal chemists (various levels from RA to Senior Director) for building collaborative and productive teams Proficiency in identifying and evaluating domestic and oversea CROs, and managing activities (e.g, discovery chemistry, scale-ups, and process development etc.) at CROs As an inventor, contributed to the discovery of two (2) marketed drugs (i.e, LFA-1/ICAM-1 antagonist Lifitegrast (SAR approved by the US FDA for treating dry eye) and HCV NS5A inhibitor Ravidasvir (PPI-668) approved by the Chinese NMPA for treating HCV), and nine (9) clinical candidates (i.e, HBV/HDV Entry inhibitor ABI-6250 (Phase 1b), HSV inhibitor ABI-5366 (Phase Ib), HBV CpAM ABI-4334 (Phase Ib), Cardiac myosin inhibitor BMS-986435/MYK-224 (Phase II), Cardiac myosin activator danicamtiv (MYK-491)(Phase II), HCV NS5A inhibitor PPI-461 (Phase I), HCV NS5B inhibitor PPI-383 (Phase I), BTK inhibitor vecabrutinib (SNS-062)(Phase Ib/II), and pan-Aurora kinase inhibitor SNS-314 (Phase I)). A co-author of 40+ peer-reviewed scientific publications and a co-inventor of 70+ WIPO PCT patent applications and issued US patents
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.